Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Antiplatelet and Anticoagulant Drugs for Coronary Artery Disease

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share

You must be a subscriber to see the full topic content.

  • KeyboardArrowRight

    Overview and Recommendations

    • Background

    • Management

  • Related Summaries

  • Overview

  • KeyboardArrowRight

    Recommendations from Professional Organizations

    • American College of Cardiology/American Heart Association (ACC/AHA)

    • European Society of Cardiology (ESC)

    • American College of Chest Physicians (ACCP)

    • National Institute for Health and Care Excellence (NICE)

    • Recommendations for patients with atrial fibrillation

  • KeyboardArrowRight

    Aspirin

    • Efficacy

    • Risk of bleeding

    • Adherence

    • Platelet reactivity

  • KeyboardArrowRight

    P2Y12 Inhibitors

    • General information

    • Clopidogrel (Plavix)

    • Prasugrel (Effient)

    • Ticagrelor (Brilinta)

    • Cangrelor

    • Ticlopidine (Ticlid)

  • KeyboardArrowRight

    Other Antiplatelet Drugs

    • Dipyridamole

    • Triflusal

    • Vorapaxar

  • KeyboardArrowRight

    Combined Antiplatelet Therapy

    • KeyboardArrowRight

      Dual antiplatelet therapy

      • Duration of dual antiplatelet therapy (DAPT)

      • Shorter duration dual-antiplatelet therapy

      • Extended duration dual-antiplatelet therapy

      • Dual antiplatelet therapy (DAPT) clinical decision rule or DAPT score

      • Dual-antiplatelet therapy vs. other therapies

    • Triple antiplatelet therapy

  • KeyboardArrowRight

    Anticoagulants

    • KeyboardArrowRight

      Vitamin K antagonists

      • Warfarin after acute coronary syndrome

      • Warfarin after myocardial infarction

    • Direct thrombin inhibitors

    • Direct factor Xa inhibitors

    • KeyboardArrowRight

      Low-molecular-weight heparins

      • Dalteparin

      • Enoxaparin

  • KeyboardArrowRight

    Additional Considerations

    • Risk for bleeding

    • Efficacy in chronic kidney disease

  • KeyboardArrowRight

    Quality Improvement

    • Physician Quality Reporting System Quality Measures

  • KeyboardArrowRight

    Guidelines and Resources

    • KeyboardArrowRight

      Guidelines

      • International guidelines

      • United States guidelines

      • United Kingdom guidelines

      • Canadian guidelines

      • European guidelines

    • Review articles

  • Patient Information

  • KeyboardArrowRight

    ICD Codes

    • ICD-10 codes

  • KeyboardArrowRight

    References

    • General references used

    • Recommendation grading systems used

    • Synthesized Recommendation Grading System for DynaMed

    • DynaMed Editorial Process

    • Special acknowledgements

    • How to cite

Topic Editor
Maria Sciammarella MD
KeyboardArrowDown
Affiliations

Associate Clinical Professor, University of California, San Francisco; California, United States

Conflicts of Interest

Dr. Sciammarella declares no relevant financial conflicts of interest.

Recommendations Editor
Esther Jolanda van Zuuren MD
KeyboardArrowDown
Affiliations

Head of Allergy, Dermatology, and Venereology, Leiden University Medical Centre; Netherlands

Conflicts of Interest

Dr. van Zuuren declares no relevant financial conflicts of interest.

Deputy Editor
Peter Oettgen MD
KeyboardArrowDown
Affiliations

Editor in Chief, DynaMed; Cardiologist, Beth Israel Deaconess Medical Center; Massachusetts, United States; Associate Professor of Medicine, Harvard Medical School; Massachusetts, United States

Conflicts of Interest

Dr. Oettgen declares no relevant financial conflicts of interest.

CheckCircle

top